Roche's new drug taselisib in combination with conventional hormone therapy could slow the growth of advanced breast cancer

recently, in a Phase 3 clinicaltrial, Roche'snew drug(combined with conventional hormone therapy) could slow the growth of advanced breast cancer and reduce the risk of cancer deterioration by 30 percenttaselisibtaselisib is the first new drug to specificappy a class of PIK3K protein (PIK3CA)In ER-positive breast cancer patients, THE PIK3CA gene mutation is quite commonIn response to this mutation, it is also expected to bring better disease control to breast cancer patientsthe study
in a large Phase 3 clinical trial, researchers recruited 516 patients with advanced or metastatic breast cancer, all of whom had ER-positive, HER2-negative breast cancers, and had deteriorated or relapsed after initial aromatase inhibitor treatmentthe researchers were divided into two groups, one receiving fulvestrant and a placebo (176 people) and the other receiving fulvestrant and taselisib (340 people)studies showed that patients who received the combination therapy had a 30 percent lower risk of cancer deteriorationIn addition, the treatment of taselisib can further delay the deterioration of the cancer by up to 2 months (7.4 months in the treatment group and 5.4 months in the control group)In terms of remission rates, the data for the treatment group was 28%, more than double the 11.9% in the control groupCurrently, the researchers do not have data on the overall survival ratethe scientists also found that in North America and Europe, the combination therapy was more effectiveSubsequent studies will shed light on the reasons behind it